3/18
10:00 am
lgvn
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
Medium
Report
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
3/18
09:44 am
lgvn
Longeveron (LGVN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
High
Report
Longeveron (LGVN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/17
07:26 pm
lgvn
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/17
04:05 pm
lgvn
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Low
Report
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
3/16
09:39 am
lgvn
Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results [Yahoo! Finance]
High
Report
Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results [Yahoo! Finance]
3/12
05:07 pm
lgvn
A $30 Million Reason to Buy Penny Stock Longeveron Today [Yahoo! Finance]
High
Report
A $30 Million Reason to Buy Penny Stock Longeveron Today [Yahoo! Finance]
3/12
09:00 am
lgvn
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Low
Report
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
3/11
04:05 pm
lgvn
Longeveron Announces Closing of Private Placement of up to $30 Million
Low
Report
Longeveron Announces Closing of Private Placement of up to $30 Million
3/10
09:00 am
lgvn
Longeveron Announces Private Placement of up to $30 Million
High
Report
Longeveron Announces Private Placement of up to $30 Million
2/25
11:26 am
lgvn
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell [Yahoo! Finance]
Medium
Report
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell [Yahoo! Finance]
2/25
11:05 am
lgvn
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
Medium
Report
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
2/13
04:41 pm
lgvn
Longeveron appoints new CEO [Seeking Alpha]
Low
Report
Longeveron appoints new CEO [Seeking Alpha]
2/13
04:30 pm
lgvn
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
Low
Report
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
2/5
09:15 am
lgvn
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Medium
Report
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
1/29
09:15 am
lgvn
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Medium
Report
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
1/26
09:23 am
lgvn
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) [Yahoo! Finance]
Medium
Report
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) [Yahoo! Finance]
1/26
09:15 am
lgvn
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Medium
Report
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
12/29
09:37 am
lgvn
Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 [Yahoo! Finance]
Medium
Report
Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 [Yahoo! Finance]
12/29
09:15 am
lgvn
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Low
Report
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026